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Summary
Background Monitoring knowledge of HIV status among people living with HIV is essential for an effective national 
HIV response. This study estimates progress and gaps in reaching the UNAIDS 2020 target of 90% knowledge of 
status, and the efficiency of HIV testing services in sub-Saharan Africa, where two thirds of all people living with 
HIV reside.
Methods For this modelling study, we used data from 183 population-based surveys (including more than 2·7 million 
participants) and national HIV testing programme reports (315 country-years) from 40 countries in sub-Saharan 
Africa as inputs into a mathematical model to examine trends in knowledge of status among people living with HIV, 
median time from HIV infection to diagnosis, HIV testing positivity, and proportion of new diagnoses among all 
positive tests, adjusting for retesting. We included data from 2000 to 2019, and projected results to 2020.
Findings Across sub-Saharan Africa, knowledge of status steadily increased from 5·7% (95% credible interval [CrI] 
4·6–7·0) in 2000 to 84% (82–86) in 2020. 12 countries and one region, southern Africa, reached the 90% target. 
In 2020, knowledge of status was lower among men (79%, 95% CrI 76–81) than women (87%, 85–89) across 
sub-Saharan Africa. People living with HIV aged 15–24 years were the least likely to know their status (65%, 62–69), 
but the largest gap in terms of absolute numbers was among men aged 35–49 years, with 701 000 (95% CrI 
611 000–788 000) remaining undiagnosed. As knowledge of status increased from 2000 to 2020, the median time to 
diagnosis decreased from 9·6 years (9·1–10) to 2·6 years (1·8–3·5), HIV testing positivity declined from 9·0% 
(7·7–10) to 2·8% (2·1–3·9), and the proportion of first-time diagnoses among all positive tests dropped from 
89% (77–96) to 42% (30–55).
Interpretation On the path towards the next UNAIDS target of 95% diagnostic coverage by 2025, and in a context of 
declining positivity and yield of first-time diagnoses, disparities in knowledge of status must be addressed. Increasing 
knowledge of status and treatment coverage among older men could be crucial to reducing HIV incidence among 
women in sub-Saharan Africa, and by extension, reducing mother-to-child transmission.
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Council; MRC Centre for Global Infectious Disease Analysis; UK Foreign, Commonwealth & Development Office.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction 
Efficient and effective HIV testing services are a key 
component of efforts to end the AIDS epidemic. A positive 
diagnosis enables people living with HIV to receive life-
saving antiretroviral therapy (ART)1 and, for pregnant 
women living with HIV, risk of mother-to-child HIV 
transmission can be almost entirely prevented.2 At the 
population level, early diagnosis and treatment could 
reduce incidence by dramatically lowering viraemia such 
that those with a suppressed viral load are unable to 
contribute to onward transmission.3 HIV testing services 
also help to identify people who are vulnerable to HIV 
acquisition and link them to effective HIV prevention 
services.4
In sub-Saharan Africa, where more than two thirds of 
people living with HIV reside, HIV testing services 
were initially provided through voluntary counselling 
and testing upon request in stand-alone sites.5 As ART 
became more widely available, provider-initiated HIV 
testing and counselling emerged, expanding HIV testing 
to all patients in health facilities. HIV testing services 
were also integrated into antenatal care, which greatly 
increased testing coverage among pregnant and post-
partum women.5 Such facility-based services were 
gradually expanded and implementation of community-
based services enabled underserved rural and marginal-
ised key populations to be reached by HIV testing and 
treatment services.6–8 The development of new testing 
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technologies and strategies—including point-of-care 
rapid diagnostic tests, self-testing, partner testing, 
and home-based testing—provided opportunities to 
accelerate delivery of results and linkage to care.9
Recognising the individual and population benefits of 
HIV testing and treatment, in 2014, UNAIDS proposed 
ambitious targets to strengthen the HIV treatment and 
care cascade such that, by 2020, 90% of people living 
with HIV would know their status, 90% of those 
diagnosed would receive ART, and 90% of those treated 
would have a suppressed viral load, with each target 
increasing to 95% by 2025.10 These targets have been 
widely adopted globally, and have motivated shifts in 
the delivery of HIV testing services, especially in sub-
Saharan African countries with the greatest epidemic 
burden. Countries monitor and report annually to 
UNAIDS their progress towards these targets.
However, the proportion of people living with HIV 
who know their status is particularly challenging to 
monitor in sub-Saharan Africa because neither the 
number of people living with HIV, nor the number who 
are diagnosed, are directly counted. Estimates for people 
living with HIV typically come from mathematical 
models synthesising HIV serosurvey and antenatal 
testing data—eg, the UNAIDS-supported Spectrum 
model.11 Aggregate HIV testing services data including 
the number of HIV tests done and number of HIV 
diagnoses are routinely collected, but reports are often 
not deduplicated and rates of retesting and re-diagnosis 
can be high.12,13 Household surveys provide cross-
sectional data about testing history by HIV status at 
roughly 5-year intervals in most countries, but only a 
few surveys directly ask respondents if they are aware 
of their HIV status, a sensitive question that has high 
potential for non-disclosure.14 These challenges are 
compounded by imprecise estimates for the number of 
new infections by age, sex, and geographical area, and 
by incomplete ascertainment of mortality among the 
previously diagnosed and undiagnosed population.
Having recently passed the deadline for UNAIDS’ 
interim 2020 target, we sought to evaluate progress 
towards the so-called “first 90” HIV diagnosis target 
in sub-Saharan Africa, describe the impact of HIV testing 
services programmes on knowledge of HIV-positive status 
and timeliness of HIV diagnosis over the 2000–20 period, 
and identify remaining gaps in who is being reached by 
HIV testing services. We synthesised data from 40 sub-
Saharan African countries about HIV testing history from 
population-based surveys, HIV testing pro gramme data, 
and HIV epidemic indicators using a mathematical 
model.12 In addition to trends in knowledge of status and 
diagnosis gaps, we estimated time from HIV infection to 
diagnosis, probability of being tested before reaching a 
given time since infection or CD4 cell count, percentage 
of tests found positive, diagnosis yield, and proportion of 
new diagnoses among positive tests.
Research in context
Evidence before this study
One of the major health policy objectives of the past decade in 
the global HIV response has been the adoption of targets to end 
the AIDS epidemic by 2030. UNAIDS and its partners put forth 
in 2014 the 90-90-90 objectives to increase HIV diagnosis, 
treatment, and viral load suppression by 2020. There is clear 
evidence of increases in treatment coverage in sub-Saharan 
Africa, but little attention has been devoted to the so-called 
first 90 and trends in knowledge of status have not been 
systematically reviewed and compared.
We searched PubMed from inception to March 31, 2020, without 
language restriction with the terms “HIV”[Title/Abstract] AND 
(“test*”[Title/Abstract] OR “diagnos*”[Title/Abstract] OR 
“knowledge”[Title/Abstract]) AND (“Africa”[MeSH] OR 
“Africa”[Title/Abstract]), as well as the UNAIDS and WHO 
websites for HIV testing reports and guidelines. Several studies 
and reports present knowledge of status estimates for selected 
countries, but none comprehensively examined knowledge of 
status trends by country, age, and sex, or provided estimates 
of the efficiency of HIV testing services.
Added value of this study
Due to incomplete HIV surveillance data, and to non-disclosure 
of HIV-positive status in most population-based surveys, 
assessment of knowledge of status is challenging and not 
uniform in sub-Saharan Africa. By triangulating household 
survey data about the proportion of adults ever tested for HIV 
and HIV testing programme data on the total annual number 
of HIV tests done among adults using a mathematical model of 
testing behaviours, this study is the first to systematically and 
comprehensively assess how knowledge of status and 
efficiency of HIV testing services have evolved in sub-Saharan 
Africa over 20 years, with stratification by sex, age, and region.
Implications of the available evidence
The past two decades have witnessed remarkable increases in 
knowledge of status across sub-Saharan Africa, but stark sex, 
age, and regional disparities remain, even in countries that 
have met the 90% target overall. Concomitant decreases in 
median time to diagnosis, HIV testing positivity, 
and proportion of new diagnoses among all positive tests 
highlight one of the major challenges faced by testing 
programmes: targeting of HIV testing services to achieve 
greatest yield of new diagnoses as the undiagnosed 
population shrinks and diagnosis delays are reduced. 
With national HIV control programmes now contemplating 
how to reach the next UNAIDS target of 95% diagnostic 
coverage by 2025, there is a need to focus on addressing 
disparities in knowledge of status and to better understand 
retesting patterns.
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Methods 
Mathematical model 
We previously developed and validated a compartmental 
deterministic mathematical model, Shiny90,12 to synthe-
sise multiple data sources into a coherent framework to 
estimate knowledge of status. Briefly, Shiny90 models 
the transition of individuals aged 15 years or older 
between six stages: (1) HIV-susceptible individuals who 
have never been tested, (2) HIV-susceptible individuals 
who have been tested, (3) people living with HIV who 
have never been tested, (4) people living with HIV 
who are unaware of their status and have ever been 
tested, (5) people living with HIV who are aware of their 
status and not on ART, and (6) people living with HIV 
who are on ART. Household surveys and HIV testing 
programme data are used to estimate the rates of HIV 
testing among adults not living with HIV and those 
living with HIV, where HIV testing rates vary with 
calendar time, sex, age, previous HIV testing status, 
awareness of status, and, for people living with HIV, 
CD4 cell count category (as a marker of risk of AIDS-
related symptoms motivating care seeking and HIV 
testing).12 In this way, the proportion of people living 
with HIV who know their status, as estimated by 
Shiny90, is bounded by ART coverage (minimum) and 
the proportion of people living with HIV who have ever 
been tested and received the results (maximum).
Data sources and model calibration 
Shiny90 uses inputs for HIV incidence, mortality, and 
ART coverage estimated and reported by national govern-
ments from the UNAIDS-supported Spectrum modelling 
software and its Estimation and Projection Package.11 
Spectrum calculates epidemic statistics stratified by age, 
sex, CD4 cell count category, and ART status. Parameter 
estimates for HIV disease progression and mortality, as 
well as demographic rates, are also informed by Spectrum.
Two main data sources were used for estimation of HIV 
testing rates during model calibration for each country. 
The first source was the proportion of individuals aged 
15 years or older who self-report having ever been tested 
for HIV and received the result of their last HIV test, 
obtained from national household surveys conducted 
between 2000 and 2019. Estimates were stratified by sex, 
age (15–24, 25–34, and 35–49 years), and, if available, HIV 
serostatus. The model was calibrated to data on the 
proportion ever tested for HIV. We did not calibrate to 
self-reported awareness of status data, due to evidence of 
non-disclosure.14 The second source was data on the total 
annual number of HIV tests done among individuals 
aged 15 years or older and, where available, the total 
number of positive HIV tests done between 2000 and 
2019 reported by national HIV testing programmes.
Countries with at least one available survey that 
measured HIV seroprevalence, or countries with surveys 
that did not collect HIV biomarkers but had at least one 
HIV testing programme dataset including the total 
number of positive tests between 2000 and 2019, were 
included in our analyses. These were the minimal set 
of survey and HIV testing programme data that were 
required to calibrate the model for a given country. 
Countries with a population of fewer than 250 000 people, 
without available survey data, or with only survey data 
without HIV biomarkers and no HIV testing programme 
data between 2000 and 2019, were excluded from 
analyses.
For each country, rates of HIV testing by sex, age, HIV 
status, and testing and treatment history were estimated 
by the model using a Bayesian framework. The mode of 
the posterior distribution was estimated via optimisation 
with the Broyden-Fletcher-Goldfarb-Shanno algorithm 
and the posterior density was approximated via a Laplace 
approximation around the posterior mode.12 Conceptually, 
the HIV testing programme data inform rates of HIV 
testing in the population, while changes in the proportion 
ever tested by HIV status, sex, and age, alongside estimates 
of HIV incidence and mortality, inform the proportion 
of tests done that are among those being HIV tested or 
diagnosed for the first time versus repeat testing (ie, 
adjusting for retesting).12
Statistical analysis 
Using Shiny90, we calculated annual (2000–20) pro-
portions of people living with HIV with knowledge of 
status (percentage of all people living with HIV who 
have ever tested HIV-positive and are thus aware of their 
HIV status), positivity (percentage of all HIV tests that 
are positive), yield of new diagnoses (percentage of new 
diag noses out of all HIV tests), and the proportion of 
new diagnoses out of all positive tests. For post-2019 
model predictions, rates of HIV testing were assumed to 
remain constant at their 2019 values, but with amplified 
un certainty guided by variation in historical testing 
rates. These projections were also guided by historical 
increases in ART coverage, with coverage achieved 
in 2020 extra polated from the rates of ART initiation in 
2016–19. No adjustments were made for the possible 
impact of COVID-19 disruptions in 2020. All indicators 
can be stratified by sex and age group, and aggregated to 
the regional level by weighting each country’s yearly 
indicator by the number of people living with HIV. 
Countries were classified by region using UN definitions.
From the annual testing rates by sex, age, HIV testing 
history, and CD4 cell count, we calculated several cross-
sectional indicators using period life-table methods15 that 
account for the competing risk of AIDS-related death. 
These include time from HIV infection to diagnosis, 
probability of getting tested within 1 year after infection, 
and probability of getting tested before reaching a 
CD4 count threshold of less than 350 cells per µL. These 
indicators were calculated annually by constructing period 
life tables for each of the 16 baseline strata of sex 
(men vs women), age groups (15–24, 25–34, 35–49, and 
≥50 years), and HIV testing history (never tested vs ever 
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tested). Because the estimates are from period life tables, 
they reflect the distribution of time to diagnosis if a person 
who seroconverted in a given year was to experience that 
year’s HIV testing rates by age and CD4 category for their 
remaining lifetime. Details of the calculations are shown 
in the appendix (p 1).
We obtained uncertainty intervals by drawing 
1000 samples from the posterior distribution of the 
testing rates estimated by Shiny90. We summarised all 
indicators using the median and 95% credible intervals 
(CrIs; 2·5th and 97·5th percentiles) of their posterior 
distribution. We did all analyses using R (version 3.5.1) 
Figure 1: Summary of included surveys and HIV testing services programme data by country and year, 2000–19
Surveys with white dots are those where results on the proportion of individuals who self-report having ever been tested for HIV are not available by HIV status. 
Horizontal lines represent HIV testing services programme data. DHS=Demographic Health Survey. AIS=AIDS Indicator Survey. MICS=Multiple Indicator Cluster 
Survey. PHIA=Population-based HIV Impact Assessment Survey. *Other types of surveys include Population Health Survey from Eritrea; South African National HIV 
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and the Rcpp packages, and Shiny90’s code is publicly 
available. We followed the Guidelines for Accurate and 
Transparent Health Estimates Reporting (appendix p 9).
All analyses were done on anonymised and deidentified 
data. All survey protocols have been approved by the 
Internal Review Board of ICF International in Calverton 
(MD, USA) or by the relevant country authorities. Ethics 
approval for secondary data analyses was obtained from 
McGill University’s Faculty of Medicine Institutional 
Review Board (A10-E72-17B).
Role of the funding source 
The funders of the study played no role in study design, 
data collection, data analysis, data interpretation, or writing 
of the report.
Results 
40 countries, 183 population-based surveys (>2·7 millions 
individuals), and 315 country-years of HIV testing pro-
gramme data reports informed our model (figure 1). 
Four sub-Saharan African countries (Cape Verde, Central 
African Republic, Guinea-Bissau, and Mauritius) were 
excluded from the analyses due to insufficient data inputs 
for model calibration, and one (São Tomé and Príncipe), 
because of high uncertainty in epidemic statistics for 
small population sizes (<250 000 people). Results of the 
Shiny90 model calibration are presented in the appendix 
(pp 16–57).
Across sub-Saharan Africa, the proportion of adults 
aged 15 years or older estimated to have been tested for 
HIV, regardless of HIV status, increased by 48 percentage 
points from 2000 to 2020 (table). Testing coverage was 
highest in southern Africa, with 85% (95% CrI 83–88) of 
adults projected to have ever been tested in the region in 
2020 (table).
The proportion of people living with HIV with know-
ledge of status increased steadily from 5·7% (95% CrI 
4·6–7·0) in 2000 to 84% (82–86) in 2020 in sub-Saharan 
Africa (table). While knowledge of status increased 
dramatically in all four sub-Saharan African regions, 
knowledge of status was consistently lower in western 
and central Africa than in eastern and southern Africa 
(figure 2A; appendix p 2). Within the regions, national 
estimates were also highly heterogeneous, especially in 
eastern Africa, with a 77 percentage-point difference 
between the countries with the lowest (Madagascar) 
and highest (Kenya) knowledge-of-status estimates in 
2020. Overall, we projected that 12 countries and one 
region, southern Africa, reached at least 90% knowledge 
of status in 2020 (figure 3). Countries with higher 
knowledge of status tended to be those in which the 
annual number of tests relative to the total population 
aged 15 years or older was highest (appendix p 3).
Across sub-Saharan Africa in 2020, men had lower 
knowledge of status (79%, 95% CrI 76–81) than did women 
(87%, 85–89), and 15–24-year-olds were the least likely to 
know their status (65%, 62–69; figure 2; appendix p 11). 
Sub-Saharan Africa Western Africa Central Africa Eastern Africa Southern Africa
Proportion of individuals ever tested for HIV among overall population aged 15 years or older
2000 3·6% (3·0–4·4) 3·1% (2·6–3·8) 1·9% (1·3–2·6) 3·3% (2·8–3·9) 10% (8·3–13)
2005 11% (10–12) 7·2% (6·6–7·8) 7·8% (6·6–9·2) 13% (12–14) 30% (29–32)
2010 30% (29–32) 19% (18–19) 19% (17–22) 41% (39–42) 59% (58–61)
2015 41% (40–42) 28% (27–29) 29% (28–30) 53% (52–54) 75% (74–75)
2020 51% (49–54) 36% (34–39) 42% (39–48) 64% (62–66) 85% (83–88)
Proportion of people living with HIV who know their HIV status
2000 5·7% (4·6–7·0) 4·0% (2·8–5·2) 3·2% (2·0–4·6) 4·8% (4·0–5·8) 9·3% (7·5–12)
2005 20% (18–22) 10% (7·7–12) 15% (12–18) 19% (17–21) 27% (25–30)
2010 53% (50–55) 33% (28–35) 37% (32–41) 56% (53–58) 60% (58–63)
2015 71% (69–73) 52% (48–55) 53% (47–56) 74% (72–75) 79% (77–80)
2020 84% (82–86) 67% (65–69) 70% (64–76) 86% (85–88) 90% (88–92)
Median time to diagnosis or AIDS-related death, years
2000 9·6 (9·1–10) 11 (10–11) 11 (10–12) 11 (10–11) 7·7 (7·0–8·4)
2005 7·2 (6·3–8·0) 10 (9·4–11) 8·2 (7·1–9·3) 7·3 (6·3–8·2) 5·9 (5·1–6·6)
2010 3·6 (3·2–4·1) 5·5 (4·9–6·5) 6·1 (5·2–7·3) 3·2 (2·8–3·6) 2·8 (2·5–3·1)
2015 3·0 (2·7–3·4) 5·2 (4·5–6·0) 4·7 (3·9–6·0) 2·6 (2·4–2·9) 2·2 (1·9–2·4)
2020 2·6 (1·8–3·5) 5·4 (4·1–6·5) 3·9 (2·2–6·0) 2·0 (1·5–2·7) 1·5 (0·9–2·3)
Probability of getting tested within 1 year after infection
2000 2·6% (2·1–3·3) 1·6% (1·1–2·1) 1·5% (1·0–2·1) 1·7% (1·4–2·1) 4·2% (3·3–5·3)
2005 5·9% (4·5–7·7) 1·8% (1·1–2·6) 5·1% (3·6–7·1) 5·8% (4·4–7·6) 7·5% (5·8–9·7)
2010 21% (18–25) 11% (7·7–14) 9·3% (6·5–13) 25% (21–29) 23% (20–26)
2015 26% (23–30) 13% (9·3–17) 12% (7·8–18) 31% (28–35) 28% (25–32)
2020 33% (23–46) 12% (7·0–19) 16% (7·6–34) 40% (29–52) 40% (26–60)
Probability of getting tested before reaching a CD4 count lower than 350 cells per µL
2000 19% (16–23) 13% (9·3–16) 12% (8·3–17) 14% (11–16) 30% (25–35)
2005 35% (29–42) 14% (9·2–19) 30% (22–38) 35% (29–42) 43% (37–50)
2010 63% (58–66) 45% (36–51) 43% (34–51) 66% (62–70) 69% (66–72)
2015 67% (63–70) 47% (38–53) 52% (41–60) 71% (68–74) 75% (72–77)
2020 71% (62–79) 44% (32–56) 59% (39–75) 77% (70–83) 81% (72–89)
HIV testing positivity
2000 9·0% (7·7–10) 3·0% (2·1–3·5) 4·6% (3·5–5·2) 11% (9·6–12) 15% (13–19)
2005 11% (9·2–14) 4·0% (3·3–4·5) 5·4% (4·2–6·7) 10% (9·1–12) 20% (16–26)
2010 5·9% (4·3–8·3) 2·6% (2·0–3·2) 5·0% (3·6–6·9) 5·6% (4·2–7·5) 13% (9·0–22)
2015 4·3% (3·5–5·2) 2·2% (1·7–2·7) 3·4% (2·4–4·7) 4·0% (3·5–4·6) 9·2% (7·1–13)
2020 2·8% (2·1–3·9) 1·9% (1·3–2·7) 2·2% (1·4–3·3) 2·5% (1·9–3·3) 5·5% (3·8–8·4)
Diagnosis yield
2000 7·9% (7·0–8·6) 2·6% (1·8–2·9) 4·2% (3·2–4·7) 9·7% (8·8–11) 13% (12–14)
2005 7·8% (7·0–8·4) 3·2% (2·7–3·6) 3·8% (3·1–4·3) 7·6% (7·0–8·1) 14% (12–15)
2010 2·8% (2·4–3·3) 1·5% (1·2–1·7) 2·6% (2·1–3·0) 2·4% (2·1–2·9) 6·9% (6·2–7·5)
2015 1·9% (1·7–2·1) 1·1% (0·9–1·3) 1·6% (1·2–1·8) 1·7% (1·6–1·8) 4·4% (4·1–4·6)
2020 1·2% (0·9–1·5) 1·0% (0·7–1·5) 0·9% (0·6–1·3) 1·0% (0·8–1·3) 2·2% (1·6–2·9)
Proportion of new HIV diagnoses among all positive tests
2000 89% (77–96) 86% (79–94) 93% (85–97) 91% (85–95) 87% (70–97)
2005 72% (55–86) 79% (71–90) 71% (55–86) 74% (61–84) 70% (48–87)
2010 48% (33–65) 56% (46–73) 52% (36–71) 44% (32–59) 53% (31–76)
2015 44% (37–53) 48% (38–61) 46% (33–59) 42% (37–48) 47% (34–60)
2020 42% (30–55) 52% (38–68) 42% (24–57) 41% (30–52) 39% (25–55)
Numbers in parentheses are 95% credible intervals.
Table: Regional progress in HIV testing-related outcomes among adults aged 15 years or older in 
sub-Saharan Africa, by year
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Such disparities were also observed among the 12 countries 
projected to achieve at least 90% of knowledge of status 
overall in 2020. Of these countries, only six (Botswana, 
Eswatini, Kenya, Lesotho, Namibia, and Rwanda) were pro-
jected to achieve 90% of knowledge of status among men, 
and none were projected to do so among 15–24-year-olds.
While the proportion of people living with HIV who are 
aware of their status was lower among younger adults, the 
absolute number of people living with HIV was also lower. 
Consequently, in absolute numbers, the largest group 
of undiagnosed people living with HIV in sub-Saharan 
Africa were men aged 35–49 years, with 701 000 (95% CrI 
611 000–788 000) left undiagnosed (figure 4; appendix p 10).
The median time from HIV infection to diagnosis (or 
death) decreased by 7 years from 2000 to 2020 for all of 
sub-Saharan Africa (table; figure 5A). That is, if projected 
HIV testing rates in 2020 persisted into the future, 
50% of people infected in 2020 would be diagnosed (or, 
with small probability, die from AIDS-related causes) 
within 2·6 years of seroconverting. National trends are 
presented in the appendix (p 4).
Consistent with the estimated decreases in median 
time to diagnosis, the probability of receiving an HIV 
test within 1 year after infection increased by 31 percen-
tage points from 2000 to 2020 in sub-Saharan Africa, 
and the probability of receiving a test before reaching 
a CD4 count threshold lower than 350 cells per µL 
increased by 52 percentage points over the same period 
(table; figure 5).
The proportion of all HIV tests that are positive 
(positivity) decreased by 6 percentage points from 2000 
to 2020, and the proportion of new diagnoses among all 
Figure 2: Progress and disparities in knowledge of HIV status in sub-Saharan Africa, 2000–20
Figure shows trends in proportion of people living with HIV who are aware of their HIV status in sub-Saharan Africa by region (A), sex (B), or age group (C). 
Shaded areas correspond to 95% credible intervals.
Figure 3: National estimates of knowledge of HIV status in sub-Saharan Africa, 2020
Bars show the proportion of people living with HIV who know their HIV status, with 95% credible intervals represented with vertical lines. The horizontal dashed line 
represents a threshold of 90% knowledge of status.
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tests (diagnosis yield) decreased by 7 percentage points 
(table; appendix p 5). Concommitantly, the proportion 
of new diagnoses among positive tests decreased by 
47 per cen tage points over the study period (table). We 
project that 58% of people living with HIV undergoing 
testing in 2020 will have been previously diagnosed 
with HIV. Quinquennial estimates are presented by sex 
and age stratification and by region in the appendix 
(pp 11–15).
Discussion 
Across sub-Saharan Africa, impressive gains were achieved 
in knowledge of status with 84% (95% CrI 82–86) of people 
living with HIV being aware of their HIV positive status, 
and 12 countries and the region of southern Africa 
projected to have reached the 90% knowledge-of-status 
target in 2020. Concomitant with these improvements, 
we estimated that median time from HIV acquisition to 
diagnosis would have been reduced to 2·6 years (1·8–3·5) 
by 2020.
Despite this progress, our results highlight substantial 
regional, national, sex, and age disparities in knowledge 
of status. Knowledge of status was consistently lower in 
western and central Africa than in eastern and southern 
Africa. In those regions, HIV prevalence is lower but key 
populations—including sex workers, men who have sex 
with men, and people who inject drugs—account for a 
higher HIV burden; for example, they generally represent 
a small fraction of the population but accounted for 42% of 
all new HIV infections in 2019 in western and central 
Africa.16 Stigma and discrimination towards key popu-
lations are common in many health facilities, which might 
lead to delayed HIV testing or poor uptake of HIV 
services.17 A systematic review and meta-analysis has 
shown that, among men who have sex with men in Africa, 
lower testing and knowledge of status were associated with 
more hostile legislation, and that knowledge of status 
remained low in the region.18 To improve coverage of 
HIV health services in western and central Africa, anti-
discrimination and protective laws to eliminate stigma 
and discrimination among key populations should be 
implemented and enforced, health workers trained and 
sensitised, and key population-friendly services provided.17 
Eastern Africa, despite having high knowledge of status 
across the region, includes the two countries with the 
lowest knowledge of status—South Sudan and Madagascar. 
While new HIV infections declined overall in eastern 
African countries between 2010 and 2019, new infections 
are estimated to have increased by 17% in South Sudan 
and 191% in Madagascar.16 This underscores that re ducing 
new HIV infections, and thus reducing the number of 
undiagnosed people living with HIV, is key to reaching 
knowledge-of-status targets.
In all four sub-Saharan African regions, and consistent 
with previous studies, men are less likely to know their 
HIV status compared with women.19 Large differences in 
knowledge of status are also observed between age groups, 
with the lowest proportion diagnosed in those aged 
15–24 years. Importantly, all countries have yet to reach 
90% knowledge of status in this younger group. This gap 
between age groups is the natural consequence of HIV 
transmission dynamics. HIV incidence is highest and 
average time since infection is short—and thus cumulative 
exposure to testing is lower—in this age group compared 
with older ones.11 To achieve 90% knowledge of status 
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Figure 4: Absolute diagnosis gaps in sub-Saharan Africa, 2020
Vertical lines represent 95% credible intervals.
Figure 5: Progress in timeliness of HIV diagnosis in sub-Saharan Africa, 2000–20
Regional trends in median time to diagnosis or AIDS-related death (A) and in the probability of being tested within 1 year of infection (B) or before reaching a CD4 count 
threshold lower than 350 cells per μL (C) were assessed through period life-table analyses. Shaded areas correspond to 95% credible intervals.
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among 15–24-year-olds would require a simultaneous 
increase in testing with greater investment in HIV pre-
vention to increase coverage of high-impact prevention 
interventions.
While we found that knowledge of status was pro-
portionally the lowest among men aged 15–24 years, 
the largest group of undiagnosed people living with 
HIV was men aged 35–49 years, with more than 700 000 
estimated to be undiagnosed in 2020. Lower uptake of 
HIV testing among men could be explained by fewer 
opportunities for testing as well as other social and 
system-wide barriers such as harmful gender norms6,20 
and inaccessible or unfriendly services.21 Engaging men 
in HIV prevention efforts is crucially important, not 
only for their own needs but also for their sexual 
partners. An increase in knowledge of status and treat-
ment coverage among older men could be crucial in 
decreasing HIV acquisition rates among women, and 
by extension, reducing mother-to-child transmission. 
Among different testing modalities, community-based 
testing, door-to-door HIV testing services, home-based 
couples testing, workplace programmes, mobile testing 
services, social network interventions, incentives to test, 
self-testing, and partner notification have shown success 
in increasing diagnostic coverage among men.22 As part 
of these efforts, facilitating linkage to and retaining 
men in HIV care remains a key challenge for further 
progress towards HIV testing and treatment targets.
Despite improvements in the median time to diagnosis 
(or AIDS-related death), if testing levels were maintained 
across sub-Saharan Africa in 2020, a projected 50% of 
people living with HIV would not be diagnosed within 
3 years following their infection, and 29% would not be 
tested before reaching a CD4 count threshold lower than 
350 cells per μL. These diagnostic delays impede rapid 
ART initiation, contributing to increased HIV morbidity 
and onwards HIV transmission.1,3 Earlier diagnosis 
should be accompanied by rapid ART linkage and long-
term adherence to ART; these are crucial to minimising 
morbidity and reducing HIV incidence.1,3
As the undiagnosed population shrinks and diagnosis 
delays are reduced, prioritisation of HIV testing services 
to achieve greatest yield of new diagnoses is one of 
the major challenges faced by testing programmes.23 
Although we noted an ecological correlation between a 
country’s testing volume with respect to its population 
of reproductive age and knowledge of status, we also 
estimated a decline in positivity and in yield of new 
diagnoses. Such declining yields are an inevitable con-
sequence of reaching saturation in testing programmes: 
as long as testing rates are lower in previously diagnosed 
individuals than in undiagnosed individuals, we can 
expect yields to decline as knowledge of status increases. 
Our analyses also highlight substantial retesting of 
people living with HIV who are already aware of their 
status. We projected that 58% of positive tests will have 
been done on previously diagnosed people living with 
HIV in sub-Saharan Africa in 2020. In previous studies 
done in sub-Saharan Africa between 2004 and 2018, 
retesting among people living with HIV with known 
HIV status was also common, ranging from 13% 
to 68%.13,24–28 Retesting can be motivated by multiple 
factors, one of them being the ability to confirm the 
accuracy of the initial test result.28–30 Another important 
driver of retesting might be avoiding disclosing one’s 
HIV-positive status due to societal stigma or denial. 
A recent study done among people undergoing HIV 
testing at a health facility in South Africa found that 
50% of patients testing HIV-positive had previously 
been in HIV care (and hence previously diagnosed). 
Among these, half did not disclose existing knowledge 
of HIV status to their health-care provider.13 Further 
research is needed to assess the potential benefits of 
retesting for re-engaging people living with HIV in care.
This analysis has some limitations. First, Shiny90 does 
not provide estimates of diagnosis coverage among 
individuals younger than 15 years of age, nor can it dis-
aggregate metrics by key population groups. Second, we 
could have overestimated knowledge of status in some 
low HIV-prevalence countries where key populations 
are disproportionately affected by HIV if these groups are 
under-represented in population-based surveys. Third, 
uncertainty in the denominator of people living with 
HIV, HIV incidence estimates, and ART coverage are not 
accounted for. This does not affect the validity of point 
estimates, but their precision could be overestimated. 
Fourth, we assumed that HIV testing does not result in 
false-negative or false-positive results. The assumption of 
no false-negative results might have slightly overest-
imated knowledge of status and testing probabilities, and 
underestimated median time to diagnosis. The number 
of HIV diagnoses reported in HIV testing programme 
data could be inflated if WHO-recommended retesting to 
verify HIV diagnosis before ART initiation was incorrectly 
counted as separate HIV diagnoses, which our model 
would not be able to identify from routinely reported data. 
Fifth, we also assumed that self-reporting of HIV testing 
histories was accurate, but social desirability and recall 
biases could result in underestimation of the proportion 
ever tested and, ultimately, of knowledge of status. How-
ever, cross-validation of self-reported HIV testing histories 
with antiretroviral biomarker data from Eswatini, Malawi, 
Tanzania, and Zambia suggest that self-reported HIV 
testing history resulted in few false negatives.31 Sixth, 
earlier estimates of diagnosis delays are informed by 
relatively few population-based survey estimates and HIV 
testing programme data. Given the cross-sectional nature 
of these metrics, they could be more sensitive to the 
elicited model’s prior distributions in early years. Finally, 
the impact of measures taken to prevent the spread of 
COVID-19 in some countries could have affected both 
HIV incidence and HIV testing services.32 Such un-
accounted factors could potentially lead to slightly lower 
knowledge-of-status estimates than those projected for 
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2020; however, a notable decrease would be unlikely since 
people living with HIV who had already been diagnosed 
would remain so.
Although previous studies have examined HIV testing 
uptake or self-reported knowledge of status at the com-
munity or country level, our analysis systematically and 
comprehensively assesses how the efficiency of HIV 
testing services evolved in sub-Saharan Africa over 
two decades. By using a unified framework to compare 
HIV testing services metrics, consistency and com-
parability of results between the different outcomes, 
countries, and regions is improved. A second strength 
is the large number of surveys and programme data 
used for tri angulation, improving the precision and 
robustness of our results. Third, in assessing time to 
diagnosis and other related metrics, we provide valuable 
information to help programmes to optimise the 
efficiency of HIV testing services.33 With clear individual 
and population-health benefits of early treatment 
initiation, reducing diagnostic delays and improving 
linkage to care will contri bute towards the ultimate goal 
to end the AIDS epidemics by 2030.
In 2014, the world adopted the goal of achieving 90% HIV 
diagnosis coverage by 2020. Sub-Saharan Africa, the most 
affected region globally, is close to reaching this target, 
with a dozen countries projected to have reached that 
goal in 2020. However, reaching high diagnosis coverage 
remains challenging and our results shed light on stark 
sex and age gaps in knowledge of HIV status. National 
HIV control programmes are now contemplating how to 
reach the next UNAIDS target of 95% diagnostic coverage 
by 2025 in a context of declining positivity, declining 
yields of true new diagnoses, and COVID-19 disruptions. 
Reaching this objective will require a better understanding 
of retesting patterns and a focus on addressing disparities 
among older men and young people in knowledge of 
status.
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